Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses AURA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AURA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Elisabet de los Pinos | $645,483 | $0 | $1,492,378 | $1,513,293 | $284,013 | $0 | $21,000 | $3,956,167 |
| President, Chief Executive Officer and Director | ||||||||
| Anthony Gibney | 345,909 | 0 | 1,006,915 | 1,209,402 | 189,000 | 0 | 0 | 2,751,226 |
| Chief Financial and Business Officer | ||||||||
| J. Jill Hopkins | 551,250 | 0 | 926,477 | 469,738 | 220,500 | 0 | 21,000 | 2,188,965 |
| Chief Medical Officer and President of Research and Development | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Elisabet de los Pinos | $3,956,167 | — | — | — |
| Anthony Gibney | 2,751,226 | — | — | — |
| J. Jill Hopkins | 2,188,965 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | Greater-than-10% holder | 2026-05-07 | D | 6,922,870 | $6 | $39,044,987 | Common, indirect | Form 4 ↗ |
| Natalie C. Holles | Director | 2026-05-19 | A | 553,844 | 0 | 0 | Common | Form 4 ↗ |
| Natalie C. Holles | Director | 2026-05-19 | A | 600,118 | 0 | 0 | Common | Form 4 ↗ |
| Natalie C. Holles | Director | 2026-05-19 | A | 2,169,103 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Antony Mattessich | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Antony Mattessich | Director | 2026-06-11 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Johnson | Director | 2026-06-11 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Johnson | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Teresa Marie Bitetti | Director | 2026-06-11 | A | 15,000 | 0 | 0 | Common | Form 4 ↗ |
| Teresa Marie Bitetti | Director | 2026-06-11 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sapna Srivastava | Director | 2026-06-11 | A | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anthony Gibney | See Remarks | 2026-06-16 | D | 12,824 | 6 | 82,330 | Common | Form 4 ↗ |
| Conor Kilroy | See Remarks | 2026-07-01 | A | 14,858 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-07-07 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-07-07 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Elisabet de los Pinos | OPTION | — | — | — | — | — | $1,513,293 |
| Anthony Gibney | RSU | — | — | — | — | — | 1,006,915 |
| Anthony Gibney | OPTION | — | — | — | — | — | 1,209,402 |
| J. Jill Hopkins | RSU | — | — | — | — | — | 926,477 |
| J. Jill Hopkins | OPTION | — | — | — | — | — | 469,738 |
| Elisabet de los Pinos | RSU | — | — | — | — | — | 1,492,378 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Elisabet de los Pinos | $1,492,378 | $0 | $1,513,293 | 0.0% |
| Anthony Gibney | 1,006,915 | 0 | 1,209,402 | 0.0% |
| J. Jill Hopkins | 926,477 | 0 | 469,738 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| J. Jill Hopkins | RSU | 67,500 | — | $367,875 |
| Elisabet de los Pinos | RSU | 60,937 | — | 332,107 |
| J. Jill Hopkins | Option | 91,667 | 8.97 | — |
| Elisabet de los Pinos | Option | 128,410 | 7.77 | — |
| Elisabet de los Pinos | Option | 255,680 | 7.68 | — |
| Elisabet de los Pinos | RSU | 122,201 | — | 665,995 |
| Elisabet de los Pinos | Option | 50,782 | 10.18 | — |
| Elisabet de los Pinos | RSU | 194,320 | — | 1,059,044 |
| J. Jill Hopkins | RSU | 120,635 | — | 657,461 |
| Anthony Gibney | Option | 250,000 | 6.16 | — |
| J. Jill Hopkins | Option | 79,365 | 7.68 | — |
| J. Jill Hopkins | Option | 22,471 | 7.77 | — |
| J. Jill Hopkins | RSU | 21,386 | — | 116,554 |
| Anthony Gibney | RSU | 150,000 | — | 817,500 |
We target a general competitive position, based on independent third-party benchmark analytics to inform the mix of compensation of base salary, bonus or long-term incentives.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Teresa Marie BitettiIndependent · Compensation · Newly elected | $34,436 | $123,060 | $126,066 | $0 | $0 | $283,562 |
| David JohnsonIndependent · Board Chair · Nominating/Governance | 77,060 | 80,340 | 77,931 | 0 | 0 | 235,331 |
| Antony MattessichIndependent · Audit · Nominating/Governance (Chair) | 56,620 | 80,340 | 77,931 | 0 | 0 | 214,891 |
| Sapna Srivastava, Ph.DIndependent · Audit (Chair) | 55,000 | 80,340 | 77,931 | 0 | 0 | 213,271 |
| Elisabet de los Pinos, Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Karan TakharIndependent · Compensation · Nominating/Governance · Not standing for re-election | 0 | 0 | 0 | 0 | 0 | 0 |
| Giovanni Mariggi, Ph.DIndependent · Audit · Compensation (Chair) | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $223,116 |
| Equity awards (grant-date value) | $364,080 |
| All other compensation | $0 |
| Total cost of the board | $587,196 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Aura Biosciences | 2025 | Elisabet de los Pinos | $645,483 | $1,492,378 | $1,513,293 | $284,013 | $3,956,167 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Elisabet de los Pinos | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “2025 Summary Compensation Table”. As printed: 3,956,167. Filing ↗machine: t10 · r2 · c29 · span 480151–480160 |
| 2 | Section 01, Anthony Gibney | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “2025 Summary Compensation Table”. As printed: 2,751,226. Filing ↗machine: r4 · c28 · span 502083–502092 |
| 3 | Section 01, J. Jill Hopkins | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “2025 Summary Compensation Table”. As printed: 2,188,965. Filing ↗machine: r5 · c29 · span 513138–513147 |
| 4 | Section 03, Elisabet de los Pinos OPTION | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r2 · c17 · span 476001–476010 |
| 5 | Section 03, Anthony Gibney RSU | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r4 · c13 · span 496547–496556 |
| 6 | Section 03, Anthony Gibney OPTION | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r4 · c17 · span 497932–497941 |
| 7 | Section 03, J. Jill Hopkins RSU | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r5 · c13 · span 507607–507614 |
| 8 | Section 03, J. Jill Hopkins OPTION | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r5 · c17 · span 508990–508997 |
| 9 | Section 03, Elisabet de los Pinos RSU | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “EXECUTI VE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t10 · r2 · c13 · span 474616–474625 |
| 10 | Section 07, pay ratio | 10-K | 2026-03-30 | 0001193125-26-130401 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 11 | Section 08, Teresa Marie Bitetti | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 283,562. Filing ↗machine: t6 · r2 · c15 · span 330226–330233 |
| 12 | Section 08, David Johnson | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 235,331. Filing ↗machine: t6 · r3 · c15 · span 336261–336268 |
| 13 | Section 08, Antony Mattessich | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 214,891. Filing ↗machine: t6 · r5 · c15 · span 348536–348543 |
| 14 | Section 08, Sapna Srivastava, Ph.D | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 213,271. Filing ↗machine: t6 · r6 · c15 · span 354581–354588 |
| 15 | Section 08, Elisabet de los Pinos, Ph.D | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 16 | Section 08, Karan Takhar | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t6 · r7 · c11 · span 359228–359229 |
| 17 | Section 08, Giovanni Mariggi, Ph.D | DEF 14A | 2026-04-20 | 0001193125-26-163933 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t6 · r4 · c11 · span 340919–340920 |
| 18 | Section 02, Matrix Capital Management Company, LP 2026-05-07 | Form 4 | 2026-05-11 | 0000950142-26-001346 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Natalie C. Holles 2026-05-19 | Form 4 | 2026-05-19 | 0001580111-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Natalie C. Holles 2026-05-19 | Form 4 | 2026-05-19 | 0001580111-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Natalie C. Holles 2026-05-19 | Form 4 | 2026-05-19 | 0001580111-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Sapna Srivastava 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Antony Mattessich 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Antony Mattessich 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271165 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, David Johnson 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271168 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, David Johnson 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271168 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Teresa Marie Bitetti 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Teresa Marie Bitetti 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271171 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Sapna Srivastava 2026-06-11 | Form 4 | 2026-06-15 | 0001193125-26-271170 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Anthony Gibney 2026-06-16 | Form 4 | 2026-06-16 | 0001193125-26-272703 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Conor Kilroy 2026-07-01 | Form 4 | 2026-07-01 | 0001193125-26-292685 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Jeremy Bender 2026-07-07 | Form 4 | 2026-07-08 | 0001193125-26-298542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Jeremy Bender 2026-07-07 | Form 4 | 2026-07-08 | 0001193125-26-298542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 35 | Section 09b board cost (computed) | Computed | — | computed | Cash 223,116 + equity 364,080 + all other 0 = 587,196, summed across the director compensation table rows.machine: formula: Σ = 587,196 |
| 36 | Aura Biosciences (subject), Section 10b CEO total | DEF 14A | 2026-04-20 | 0001193125-26-163933 | CEO total compensation as printed in Aura Biosciences's own proxy. As printed: 3,956,167. Filing ↗machine: t10 · r2 · c29 · span 480151–480160 |